Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial.

摘要: Background In patients with inflammatory bowel disease (IBD) on infliximab, data are limited immune response to influenza vaccine and the impact of timing. The study aims were evaluate responses in IBD infliximab timing responses. Methods this randomized study, 137 subjects maintenance therapy allocated receive 2012/2013 inactivated at time infusion (n = 69) or midway between infusions 68). Serum was collected before after vaccination for hemagglutination inhibition titers. Serologic protection defined by postvaccine titer ≥1:40. Results Comparing vaccinated those midway, serologic achieved 67% versus 66% H1N1 (P 0.8), 43% 49% H3N2 0.5), 69% 79% B 0.2). Although solicited adverse events common (60%), no subject experienced a serious event requiring additional medical attention. Only 6% had clinically significant increase activity score, not impacted Conclusions is only approximately 45% 80% varying antigen. Yet, importantly, relative does affect achievement protection, well tolerated. Therefore, any point during scheduling recommended opportunities broaden availability convenience optimize coverage should be explored.